CG Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

CG Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$151K	Sell	17,500 -15,000	-46%	-$111K	0.06%	136
2016 Q3	$206K	Hold	32,500	–	–	0.08%	127
2016 Q2	$137K	Sell	32,500 -7,000	-18%	-$33.8K	0.06%	115
2016 Q1	$172K	Sell	39,500 -19,000	-32%	-$84.6K	0.07%	116
2015 Q4	$359K	Sell	58,500 -185,900	-76%	-$1.22M	0.14%	92
2015 Q3	$1.4M	Buy	+244,400	New	+$1.88M	0.59%	54

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CG Asset Management's PGNX Position: Q4 2016 in Review

CG Asset Management reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 46% in Q4 2016, selling an estimated $111K and leaving 17,500 shares worth $151K. The position accounts for 0.06% of the portfolio, ranked #136.

CG Asset Management first reported a position in PGNX in Q3 2015 and has held it in 6 quarters since. The position peaked at $1.4M in Q3 2015. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

CG Asset Management held 17,500 shares of Progenics Pharmaceuticals Inc worth $151K as of Q4 2016.
CG Asset Management sold 15,000 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $111K.
Progenics Pharmaceuticals Inc made up 0.06% of CG Asset Management's portfolio in Q4 2016, its #136 holding.
CG Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and has held it in 6 quarters since.
CG Asset Management's Progenics Pharmaceuticals Inc position peaked at $1.4M in Q3 2015.
126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on CG Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.